GRAIL earns UBS strong buy rating, ahead of key FDA cancer review

UBS Group upgraded GRAIL, LLC to a strong-buy rating on September 12, 2026.

The upgrade follows the company's August 5 earnings report. GRAIL reported a quarterly loss of $2.56 per share, beating consensus estimates. Quarterly revenue reached $44.69 million, exceeding analyst expectations.

The company is preparing for an FDA Advisory Committee meeting later in September. Regulators will review the Premarket Approval application for the Galleri multi-cancer early detection test. Multiple recent analyst reports indicate high financial community interest in the firm.